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ompetition for essential nutrients and/or release
of toxic metabolites are mechanisms highly
conserved in both bacteria and higher organ-
isms as innate defense systems from external
pathogens. One such mechanism is based on the activation
of indoleamine 2,3-dioxygenase (IDO), an enzyme that cata-
lyzes the catabolism of the essential amino acid tryptophan
(rev. in 1). By depleting tryptophan, IDO limits the ability of
many pathogens to synthesize proteins. In addition, activa-
tion of the enzyme results in the accumulation of tryptophan
breakdown products, collectively known as kynurenines,
some of which are toxic to bacteria and parasites.
Consistent with the enzyme effects on the containment
of pathogens’ replication and invasion, constitutive IDO
expression in higher organisms is found at mucosal inter-
faces, such as the mucosa of the intestine and the lung,
which are barriers to external microorganisms (2). How-
ever, chronic inﬂammatory processes, particularly those
sustained by interferon-driven immune responses, can
induce high levels of IDO in many cell types including
epithelial, endothelial, and myeloid cells (3–7). Intrigu-
ingly, under these conditions, active IDO appears to mute
lymphocyte immune responses by “starving” actively pro-
liferating leukocytes, thereby limiting the uncontrolled
spread of inﬂammation. Both high levels of IDO as well as
activation of the enzyme by redox active compounds
present in the inﬂammatory microenvironment are re-
quired for the immunosuppressive effect (8).
The ability of IDO to regulate lymphocyte functions has
prompted many investigators to test the effect of IDO
overexpression at transplantation sites as a mean to avert
destructive allogeneic immune responses against heart,
skin, lung, cornea, and bone marrow grafts (9–13). Along
these lines of studies, the article by Jalili et al. (14),
published in this issue of Diabetes, demonstrates that local
overexpression of IDO by ﬁbroblasts cotransplanted with
pancreatic islets can, by a bystander effect, signiﬁcantly
delay immune rejection of the graft in the absence of
immunosuppressive treatment of the host. The authors
show that IDO overexpression induces Th2 immune re-
sponses, downregulates the production of alloantigen-
speciﬁc antibodies, and induces the transient appearance
of T-cells with a regulatory phenotype in draining lymph
nodes. These ﬁndings reinforce the concept put forward in
other transplantation settings that local overexpression of
IDO may be a powerful tool to foster transplant tolerance
and shed light into mechanisms of immunoregulation
driven by this enzyme.
An intriguing ﬁnding reported by Jalili et al. is the
containment of leukocyte inﬁltration in the grafts express-
ing IDO. This effect correlated with decreased expression
of chemokines involved in T-cell recruitment. Although
previous studies have reported a decreased lymphocyte
inﬁltration in tissues overexpressing IDO, evidence was
lacking that this effect may be related to a role played by
this enzymatic pathway in controlling T-cell homing. This
possibility is consistent with the observation that certain
tryptophan metabolites downregulate the expression of
lymphocyte adhesion receptors as well as monocyte che-
moattractants in endothelial cells (15). Presently it re-
mains unclear to what extent the phenomenon described
by Jalili et al. is accounted for by the unique cellular
composition of the grafts (i.e., IDO-expressing dermal
ﬁbroblasts and islets). IDO transduction in keratinocytes
and ﬁbroblasts was reported to alter expression of genes
relevant to inﬂammatory processes (16,17). Hence, it will
be important to determine in future studies whether IDO
overexpression in skin ﬁbroblasts also results in a unique
chemokine or cytokine proﬁle capable of inﬂuencing im-
mune cell migration. Furthermore, it will be critical to
show through the use of enzymatic inhibitors (e.g., 1-methyl-
tryptophan) that the effect on graft inﬁltration by immune
cells is truly dependent on the activation of the IDO trans-
gene. Finally, IDO expression may induce other mechanisms
of immune privilege independent of chemotactic factors as
reported (18). Nevertheless, although clearly not elucidated
yet, the observation by Jalili et al. remains noteworthy, as it
suggests that, at least in the selected cellular context, control
of leukocyte trafﬁcking may be an additional mechanism by
which IDO averts immune responses.
The induction of Th2 immune responses described by
Jalili et al. is consistent with reported effects of IDO
expressed by stromal cells and professional antigen-pre-
senting cells, such as dendritic cells (DCs), on T-cell
immune responses in vitro (rev. in 19). A role of IDO in
maintaining a Th2 bias was also shown in other patholog-
ical conditions in vivo such as in animal models of asthma
(19). This Th2 bias may be functionally linked to the
observed concomitant downregulation of alloantibody
production since Th1 immune responses are required for
cognate help to B-cells and antibody responses. Hence,
local overexpression of IDO may impact on both T- and
B-cell arms of immune responses in islet transplantation
settings. Further, the evidence that T-cells with a regula-
tory phenotype accumulate in draining lymph nodes indi-
cates the potential for IDO to affect not only local immune
responses, but also to systemically facilitate immunoregu-
latory networks. This latter observation is intriguing as it
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gence of migratory antigen-presenting cells (e.g., DCs)
competent to expand regulatory T-cells (Tregs) in second-
ary lymphatic stations. A role of interferon and IDO
activation in the generation of immature immunoregula-
tory DCs was demonstrated in previous in vitro studies
(20). As Jalili et al. provide only a limited analysis of
CD11c
 cells populating the grafts, a more comprehensive
characterization of myeloid cell populations is warranted
to evaluate their role in the induction of Tregs in their
experimental setting. On the other end, such increased
frequency of Tregs appears to be transient. Further work
is needed to determine whether this result is linked to the
loss of IDO expression within the grafts over time or to the
unique features of IDO-induced Tregs (e.g., short life span
and/or reprogramming into other T-cell types).
Overall, the ﬁndings by Jalili et al. (14) are promising
and suggest the potential for islets grafts positioned in an
IDO-enriched transplant microenvironment to evade im-
mune rejection, at least transiently, through multiple
mechanisms (Fig. 1). Perhaps more effective gene transfer
approaches, ensuring persistence of high levels of IDO
expression, may improve this outcome in the future.
However, long-term, potentially toxic effects of trypto-
phan metabolites on pancreatic islets are currently
unknown. In addition, possible species-speciﬁc differ-
ences between mouse and human islets in their re-
sponse to tryptophan metabolites will have to be
carefully evaluated. It is also unknown whether, in a
transplantation setting, a chronic state of immunosup-
pression maintained by local IDO expression may select
for pathogens that are resistant to tryptophan deprivation,
thereby enhancing the risk of opportunistic infections
postsurgery. Finally, overexpression of IDO may not nec-
essarily result in enhanced tryptophan catabolism since
enzyme activation depends upon posttranslational modiﬁ-
cations inﬂuenced by the inﬂammatory microenvironment.
Hence, paradoxically, a sustained inﬂammatory microen-
vironment may be required for persistent IDO activation
and induction of immunoregulatory networks. Will it be
possible to maintain the transplant microenvironment
permissive to IDO activation without tilting the balance
toward immune rejection? How would the autoimmune
milieu of type 1 diabetic transplant recipients inﬂuence
activation of IDO delivered locally? Promising work has
begun to address some of these questions (21). However,
a more in-depth knowledge of the molecular mechanisms
triggering the activation of IDO—as well as a better
understanding of how tryptophan deprivation and/or its
metabolites functionally impact on select inﬂammatory
cell subsets—will be critical to guide possible therapeutic
strategies based on the use of IDO in clinical settings.
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FIG. 1. Overview of the effects of IDO overexpression in composite ﬁbroblasts/islet grafts as described by Jalili et al. (14). Dashed lines and
question marks indicate possible mechanisms suggested by the authors’ data.
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